Q&A Panel Discussion – New Therapy Options in Advanced Small Cell Lung Cancer (SCLC)

These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch the Q&A panel discussion with Dr Paul Mitchell, Dr Santiago Ponce-Aix, Dr Amit Jain and Dr Tanujaa Rajasekaran.

 

SCLC Webinar Chapters

Q1: Does the 3-year OS data from CASPIAN influence the long-term efficacy perception of IO + chemo in 1L ES-SCLC patients?

Q2 (Dr Tanujaa): Why is it that unlike the non-small cell lung cancer patients our small cell lung cancer patients don’t seem to respond as well to immune checkpoint inhibitors? Any idea?

Q3: Why do you think Atlantis trial failed?

Q4: In your practice what do you use as second line treatment for the platinum refractory patients? Do you use a single agent lurbinectedin or do you do the combination of lurbinectedin plus Irinotecan?

Q5:  Is lurbinectedin approved in Singapore?

Q6. Is the current trial with lurbinectedin plus atezolizumab (first line maintenance) enough for USA full approval of lurbinectedin in second line of SCLC? Or will it be necessary to launch a new phase 3 trial with lurbinectedin to get the full approval?

Q7: Thanks, Dr Santiago it’s wonderful hearing your insights as you are in the thick of it and you’re planning new trials?  What are you going to put your money on if you want your phase III, 2^nd line trial? What’s your combination of choice there’s so many ways to do this now?  So, if you had to pick one, which one would it be?

Q8: You mentioned about PD-L1 in small cell lung cancer, do you routinely test for that in your patients?

Q9: Do you routinely re-biopsy your patients who progress on first line or second line therapy?

Q10: How important is maintenance immunotherapy in first line SCLC?

Q11 (Dr Tanujaa): For example, if you have an extensive stage small cell lung cancer patient and had just had etoposide plus carboplatin as first-line therapy and they progress without any immune checkpoint inhibitor or a similar situation where limited stage lung cancer had concurrent chemo RT and progress within three months and haven’t seen immune checkpoint inhibitors and they are platinum refractory.  So, what will be your choice for second line therapy? Would you consider using immune checkpoint inhibitors in the second line or would you still go back to your standard second line chemotherapy options?

Q12: Why temozolomide for your case study? And why not other chemotherapy agents?

Q13: What do you think of drugs to treat CNS metastasis in the future? What will be the brain penetration of the newer drugs?

Q14: Do you have any data on the CNS activity of lurbinectedin?

Q15: Do you often offer local therapy after response to etoposide platinum plus immune checkpoint inhibitors? What do you think about the role of local radiotherapy in this case?

Q16: What is the most promising biomarker in SCLC according to you?

Q17: Let’s say if we were having this webinar five years down the road, do you think we will be still talking about overall survival being about what slightly more than a year or do you see things changing tremendously? What are your views?

 

ZEPZELCA^® is a registered trademark of PharmaMar SA. ZEPZELCA^® is under license from PharmaMar SA.